We characterized rabbit antisera to synthetic human calcitonin that specifically recognize the amino-and carboxy-terminal regions of calcitonin (antisera 1-506 and HMS-385, respectively), by both classical (parallelism of dose-response curves) and (owing to the unavailability of a variety of analog fragments of human calcitonin) biochemical plus enzymic alteration of synthetic human calcitonin. We used nonequilibrium double-antibody assay conditions and incubation times of 48 + 72 + 24 h. Final concentrations in the assay tube (1 mL) for 1-506 and HMS-385 were 1:100 000 and 1:200 000, respectively. Midpoint of the calcitonin dose-response curve was 95 and 425 pg in the 1-506 and HMS-385 assays, respectively. The intra-and inter-assay CV was <8 and 17%, respectively, for each assay. The HMS-385 antiserum was shown to recognize the products of chymotryptic digestion plus oxidation and reduction of the amino-terminal disulfide bond of calcitonin in addition to complete immunological recognition of a synthetic carboxy-terminal hexapeptide fragment. The 1-506 antiserum failed to recognize the calcitonin fragments after chymotrypsin digestion and the carboxy-terminal hexapeptide fragment. Immunoreactivity in the 1-506 assay was also reduced by about 90% after oxidation and reduction of the amino-terminal disulfide bond. HMS-385 cross reacted completely with rat and human calcitonin; 1-506 was completely specific only to human calcitonin. Neither antisera bound salmon, porcine, or bovine calcitonins. The immunological determinants for the HMS-385 and 1-506 antisera evidently reside in the amino acid sequence of the extreme carboxy-terminal region and the conformation plus amino acid sequence of the amino terminal, respectively.
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We characterized rabbit antisera to synthetic human calcitonin that specifically recognize the amino-and carboxy-terminal regions of calcitonin (antisera 1-506 and HMS-385, respectively), by both classical (parallelism of dose-response curves) and (owing to the unavailability of a variety of analog fragments of human calcitonin) biochemical plus enzymic alteration of synthetic human calcitonin. We used nonequilibrium double-antibody assay conditions and incubation times of 48 + 72 + 24 h. Final concentrations in the assay tube (1 mL) for 1-506 and HMS-385 were 1:100 000 and 1:200 000, respectively. Midpoint of the calcitonin dose-response curve was 95 and 425 pg in the 1-506 and HMS-385 assays, respectively. The intra-and inter-assay CV was <8 and 17%, respectively, for each assay. The HMS-385 antiserum was shown to recognize the products of chymotryptic digestion plus oxidation and reduction of the amino-terminal disulfide bond of calcitonin in addition to complete immunological recognition of a synthetic carboxy-terminal hexapeptide fragment. The 1-506 antiserum failed to recognize the calcitonin fragments after chymotrypsin digestion and the carboxy-terminal hexapeptide fragment. Immunoreactivity in the 1-506 assay was also reduced by about 90% after oxidation and reduction of the amino-terminal disulfide bond. HMS-385 cross reacted completely with rat and human calcitonin; 1-506 was completely specific only to human calcitonin. Neither antisera bound salmon, porcine, or bovine calcitonins. The immunological determinants for the HMS-385 and 1-506 antisera evidently reside in the amino acid sequence of the extreme carboxy-terminal region and the conformation plus amino acid sequence of the amino terminal, respectively.
In normal human sera, immunoreactive calcitonin was undetectable (<10-20 ng/L) in 87 and 53% of samples with the carboxy-and amino-terminal antisera, respectively. In 97% of all normal sera analyzed with both antisera, immunoreactive calcitonin was <200 ng/L. In contrast, higher concentrations of carboxy-than amino-terminal immunoreactivity were noted in extracts of normal thyroids and sera from cancer patients. 100:1, or ct-chymotrypsin (lot no. 145OCDI 37E871) in a ratio of 100:1 and 10 000:1. Before incubation, the trypsin was treated with L-1-tosylamide-2-phenylethyl-chloromethyl ketone (lot no. 97C-0164) to inhibit the contaminant a-chymotryptic activity (18 
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Radioiodination
Results
Assay Characteristics
The incubation intervalswe selectedfor adding reagents to the nonequilibrium assay systems were derived from preliminary experiments (data not shown). Utilizing the 48 + 72 + 24 h incubation periods, we could quantitatively detect calcitonin (Figure 1 )over the range of 4-1000 and 50-600 pg by the 1-506 and HMS-385 assays, respectively.
Slopes of the regression lines were each equal to 0.99. With respect to the human calcitonin dose-response curve, the midpoint was 90-100 pg and 400-450 pg in the 1-506 (Figure 2, A) and HMS-385 (Figure 2, B) assays, respectively. The minimum detectable dose varied among assays, depending upon the specific activity of the tracer and the additions to the standard curve required to make it homologous with the tubes con- Parallelism was examined between the synthetic human calcitonin dose-response curves (0-0. A-A) and dilutions of serum from patients with medullary carcinoma of the thyroid (#{149}-#{149}) and extracts of human (X-X) and rat (t-) thyroids. In addition, we tested salmon, porcine, and bovine calcitonin (U-U) for immunological cross reaction. In panel A, the uppermost abscissa coordinates refer to micrograms of rat thyroid extract plus nanograms of salmon, bovine, and porcine calcitonin. The other coordinates in the upper part of panelA refer to microliters of serumand micrograms of human thyroid extract. In panel B, the upper abscissa coordinates refer to microliters of serum,microgramsof thyroid extract plus micrograms of salmon,bovine, and porcine calcitonin. The insets show the degree of immunological recognition of the carboxy-terminal analog of human calcitonin (0-fl) by the respective antisera taming the unknowns.
In buffer alone, the minimal detectable dose was 2 and 8 pg per assay tube in the 1-506 and the HMS-385 assay, respectively.
The intra-assay and inter-assay coefficients of variation for either assay did not exceed 8 and 17%, respectively.
Specificity of Antisera
In both assays, data for dilutions of sera from patients with medullary carcinoma of the thyroid and extracts of normal human thyroids paralleled the synthetic human calcitonin standard dose-response curve ( Figure 2 , panels A and B). Dilutions of rat thyroid extract yielded an inhibition curve that paralleled the human calcitonin curve in the HMS-385 assay (Figure 2, panel B) , but not in the 1-506 assay ( Figure  2, panel A) . Salmon, porcine, and bovine calcitonins were not immunoreactive in either assay. We examined antisera recognition of the synthetic carboxy-terminal hexapeptide analog. With the 1-506 antiserum, the analog exhibited about 0.2% cross reaction (Figure 2 , insert of panel A), while it was essentially equivalent to calcitonin in the HMS-385 assay (Figure 2, insert of panel B) . Therefore, the immunological determinant for the HMS-385 assay resides in at least the carboxy-terminal hexapeptide region of calcitonin.
We investigated the immunological determinant for the 1-506 assay by analysis for immunoreactivity after exposing calcitonin both to serine proteases or to chemicals that would oxidize or reduce the amino-terminal disulfide bond. Figure  3 of the mixtures after 1-and 6-h incubations with trypsin are depicted in Figure 4 , panels A and B, We undertook additional characterization of the immunological determinant for the 1-506 antiserum by electrofocusing of the reaction products formed either by reduction or oxidation of the amino-terminal disulfide bond of human calcitonin. Analysis indicated that both reduction ( Figure 5 Thus, the data on the enzymic and chemical modification of calcitonin suggest that the immunological determinant for the 1-506 antiserum includes both the amino acid sequence (Table 1) and serum from patients with medullary carcinoma of the thyroid (Table 2 )
Discussion
A brief comment on the chemistry of the calcitonins will 
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homology between rat and human calcitonin suggests that antisera to them could be used interchangeably, apparently -.
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the amino acid differences between the peptides (at residues a-chymotrypsin activity in the particular lot of trypsin. The extremely rapid loss of immunoreactivity noted by the 1-506 assay in the a-chymotrypsin incubates indicates that a portion of the immunological determinant for this antiserum resides in the region of leucine at position 9. The initial scission at leucine 9 by a-chymotrypsin would generate two peptides, i.e., calcitonin 1-9 and 10-32. The 10-32 sequence would be slightly more basic than calcitonin, because the amino group of glycine (position 10) has a higher dissociation constant (pK,, = 9.8) than does the a-amino group of cystine (pKa 8.9). The 10-32 sequence probably corresponds to the p18.8 peptide noted in Figure 4 . The small amino-terminal 1-9 fragment lost immunoreactivity in both assays. Although calcitonin has several potential a-chymotrypsin cleavage points closer to the carboxy-terminal that would probably preserve the determinant for antiserum 1-506, these peptides were not observed in our electrophoretograms.
This would suggest that the initial action of a-chymotrypsin is to cleave human calcitonin at the leucine 9 position and then to degrade the 10-32 sequence into smaller and more basic peptides similar to those at pH 9.8 to 10.0 in Figure 4 . In summary, we have characterized antisera specific to the amino-and carboxy-terminal of human calcitonin. We have shown that the serum concentrations of immunoreactive calcitonin in normal adults were largely undetectable by both assays, e.g., <10-20 ng/L. In addition, we observed higher concentrations of carboxythan amino-terminal immunoreactive calcitonin, both in extracts of normal human thyroids and in serum from patients with medullary carcinoma of the thyroid.
